Between November 1 and November 4, a Hyperliquid address reduced its short position in Ether from 21,461.83 ETH to 11,825.63 ETH, a 44.9% decrease in token count. On November 4, the short position was valued at approximately $27.14 million with Ether trading at $2,295.40, down from a $48.69 million position on November 1 when Ether was priced at $2,268.80. This reduction in short exposure could indicate a shift in market sentiment or risk management by the holder.
Hyperliquid's Ether short position is reported at $27.14 million as of early November 2026. For readers following cryptocurrency, here is Pluang's market snapshot as of Nov 05, 2026 01:32 WIB: out of 50 major cryptocurrencies, 44 rose and 5 fell. Notable movers include BAT at Rp2.510 (+9.37%), EOS at Rp12.649 (+8.13%), and ALGO at Rp1.809 (+6.29%).
The global e-learning market is projected to grow from $275.9 billion in 2026 to $506.6 billion by 2032, with a CAGR of 10.62% driven by rising internet connectivity, corporate upskilling demands, and government digital education initiatives. North A...
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
